Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape - 04/02/24
Abstract |
Tumor immunotherapy, an innovative anti-cancer therapy, has showcased encouraging outcomes across diverse tumor types. Among these, the PD-1/PD-L1 signaling pathway is a well-known immunological checkpoint, which is significant in the regulation of immune evasion by tumors. Nevertheless, a considerable number of patients develop resistance to anti-PD-1/PD-L1 immunotherapy, rendering it ineffective in the long run. This research focuses on exploring the factors of PD-1/PD-L1-mediated resistance in tumor immunotherapy. Initially, the PD-1/PD-L1 pathway is characterized by its role in facilitating tumor immune evasion, emphasizing its role in autoimmune homeostasis. Next, the primary mechanisms of resistance to PD-1/PD-L1-based immunotherapy are analyzed, including tumor antigen deletion, T cell dysfunction, increased immunosuppressive cells, and alterations in the expression of PD-L1 within tumor cells. The possible ramifications of altered metabolism, microbiota, and DNA methylation on resistance is also described. Finally, possible resolution strategies for dealing with anti-PD-1/PD-L1 immunotherapy resistance are discussed, placing particular emphasis on personalized therapeutic approaches and the exploration of more potent immunotherapy regimens.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Tumor immune escape mechanisms contribute to immunotherapy resistance. |
• | PD-1/PD-L1 signaling pathway regulates immune evasion by tumors. |
• | Tumor antigen deletion and T cell impact response to anti-PD-1/PD-L1 therapy. |
• | Alterations in PD-L1 expression and metabolism impact immunotherapy resistance. |
• | Targeted therapies and personalized treatment promise to overcome drug resistance. |
Keywords : Tumor immunotherapy, Immunotherapy resistance, Immune escape, Anti-PD-1/PD-L1 therapy, PD-1/PD-L1
Plan
Vol 171
Article 116203- février 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?